What is ITRM stock price today?

ITRM (Iterum Therapeutics Plc) stock is trading at $0.03 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ITRM stock going up or down today?

ITRM stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ITRM stock now?

The decision to buy ITRM depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ITRM a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ITRM based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ITRM stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ITRM is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ITRM's P/E ratio?

P/E ratio data for ITRM will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ITRM's market cap?

ITRM (Iterum Therapeutics Plc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is ITRM's price to book ratio?

ITRM trades at a price-to-book (P/B) ratio of 0.43, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ITRM pay dividends?

ITRM does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ITRM's dividend yield?

ITRM does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ITRM stock a good long-term investment?

ITRM's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ITRM's revenue growth rate?

ITRM has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ITRM are available on our dashboard with complete income statement analysis.

What are the risks of investing in ITRM?

Key risks for ITRM include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ITRM compare to its competitors?

Compare ITRM to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ITRM's performance and positioning.

What is ITRM's stock price target for 2026?

Our AI model provides price targets for ITRM based on fundamental analysis: Bull case $0.04 (+30%), Base case $0.03 (+15%), Bear case $0.03 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ITRM?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ITRM. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ITRM's next earnings report?

ITRM reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ITRM - Iterum Therapeutics Plc

NYSE * Health Care * Biotechnology

$0.03

+$0.01 (+20.00%)

About Iterum Therapeutics Plc

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Key Statistics

Market Cap

$1.60M

P/B Ratio

0.43

EPS

$-0.72

Revenue Growth

-1.0%

Employees

How ITRM Compares to Peers

ITRM is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ITRM(This stock)	$1.60M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Iterum Therapeutics Plc Company Information

Headquarters: Ireland
Website: www.iterumtx.com
Sector: Health Care
Industry: Biotechnology

ITRM - Iterum Therapeutics Plc

About Iterum Therapeutics Plc

ITRM Key Statistics

How ITRM Compares to Peers

Iterum Therapeutics Plc Company Information

ITRM Lician Score

ITRM Financial Snowflake

Upcoming Events for ITRM